GPT and metabolic dysfunction-associated steatohepatitis: The first study [17] was in 10 biopsy-proven NASH patients administered pemafibrate (0.1 mg) twice a day for 24 weeks; their AST and ALT values were significantly decreased, especially in NASH patients with significant activity and advanced fibrosis.